Back grey_arrow_rt.gif
 
 
Preventing Liver Cancer: primary & secondary Prevention
 
 
  From Hepatology Research
 
"Antiviral therapy, mainly with interferon, is recommended to prevent carcinogenesis in patients with chronic hepatitis C or compensated hepatitis C virus-related cirrhosis......If any chronic hepatitis B, chronic hepatitis C or cirrhosis is present, such patients constitute a high-risk group for hepatocellular carcinoma.....In particular, patients with cirrhosis type B or C belong to the very high-risk group......we propose performing ultrasonography once every 3-4 months for the very high-risk group and once every 6 months for the high-risk group......the current standard treatment, namely, combined therapy with pegylated interferon and ribavirin, has been shown to yield a higher complete response rate and is expected to contribute substantially to the prevention of development of liver cancer in the future......For chronic hepatitis B, nucleoside analogs are becoming established as the standard treatment."
 
"HEPATOCELLULAR CARCINOMA has been shown to be causally related to chronic hepatitis B and C, and also to various chronic liver diseases other than viral hepatitis. Most patients with hepatocellular carcinoma have underlying cirrhosis. Therefore, prevention of these causal hepatic diseases, particularly of viral hepatitis, would lead to prevention of hepatocellular carcinoma. Prophylaxis against mother-to-child transmission of hepatitis B and prevention of hepatitis C associated with medical interventions, for example, blood transfusion, is strongly recommended as a secondary prevention measure against the development of chronic viral hepatitis and hepatocellular carcinoma. With the introduction of vaccination to prevent mother-to-child transmission in 1986 and of blood donor screening in 1989, the incidence of new carriers of both hepatitis B and C, respectively, has been reduced to a very low level. Viewed from this perspective, it can be hoped that eradication of hepatocellular carcinoma attributable to viral hepatitis may eventually be achieved."
 
FREE online access available
Clinical Practice Guidelines for Hepatocellular Carcinoma - The Japan Society of Hepatology 2009 update-

 
The committee for revision of the Clinical Practice Guidelines for Hepatocellular Carcinoma
 
Preface: The 2009 version
 
Surveillance algorithm and diagnostic algorithm for hepatocellular carcinoma
 
Treatment algorithm for hepatocellular carcinoma
 
Chapter 1: Prevention
 
Chapter 2: Diagnosis and surveillance
 
Chapter 3: Surgery
 
Chapter 4: Chemotherapy and radiotherapy
 
Chapter 5: Transcatheter arterial chemoembolization
 
Chapter 6: Local ablation therapy
 
Level of evidence
 
Grades of recommendation
 
Published work search formulae
 
Comments from Paramedic Member 1
 
Comments from Paramedic Member 2
 
Fish model leads to new findings in liver disease
 
Edited by
Hirohito Tsubouchi
 
Print ISSN: 1386-6346
Online ISSN: 1872-034X
 
Frequency: Monthly
 
 
 
 
  icon paper stack View Older Articles   Back to Top   www.natap.org